Monte Rosa Therapeutics, Inc. (GLUE)
9.31
-1.00
(-9.70%)
USD |
NASDAQ |
Nov 12, 16:00
9.80
+0.49
(+5.26%)
After-Hours: 04:02
Monte Rosa Therapeutics Enterprise Value : 253.90M for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 253.90M |
| November 11, 2026 | 339.34M |
| November 10, 2026 | 355.57M |
| November 09, 2026 | 362.40M |
| November 06, 2026 | 361.55M |
| November 05, 2026 | 334.21M |
| November 04, 2026 | 382.91M |
| November 03, 2026 | 347.88M |
| November 02, 2026 | 366.67M |
| October 30, 2026 | 377.78M |
| October 29, 2026 | 387.18M |
| October 28, 2026 | 385.47M |
| October 27, 2026 | 369.24M |
| October 26, 2026 | 353.86M |
| October 23, 2026 | 384.61M |
| October 22, 2026 | 407.68M |
| October 21, 2026 | 417.08M |
| October 20, 2026 | 429.04M |
| October 19, 2026 | 369.24M |
| October 16, 2026 | 290.64M |
| October 15, 2026 | 323.10M |
| October 14, 2026 | 299.18M |
| October 13, 2026 | 303.45M |
| October 12, 2026 | 357.28M |
| October 09, 2026 | 338.48M |
| Date | Value |
|---|---|
| October 08, 2026 | 340.19M |
| October 07, 2026 | 327.38M |
| October 06, 2026 | 301.75M |
| October 05, 2026 | 335.92M |
| October 02, 2026 | 355.57M |
| October 01, 2026 | 420.50M |
| September 30, 2026 | 477.73M |
| September 29, 2026 | 417.44M |
| September 28, 2026 | 414.88M |
| September 25, 2026 | 420.00M |
| September 24, 2026 | 415.74M |
| September 23, 2026 | 430.22M |
| September 22, 2026 | 490.74M |
| September 21, 2026 | 461.76M |
| September 18, 2026 | 450.68M |
| September 17, 2026 | 490.74M |
| September 16, 2026 | 495.00M |
| September 15, 2026 | 523.97M |
| September 14, 2026 | 601.53M |
| September 11, 2026 | 616.02M |
| September 10, 2026 | 637.32M |
| September 09, 2026 | 632.21M |
| September 08, 2026 | 633.06M |
| September 04, 2026 | 596.42M |
| September 03, 2026 | 642.44M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| United Therapeutics Corp. | 23.08B |
| ACADIA Pharmaceuticals, Inc. | 2.230B |
| Alnylam Pharmaceuticals, Inc. | 20.38B |
| Anika Therapeutics, Inc. | 166.16M |
| Savara, Inc. | 870.84M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 3.063M |
| Revenue (Quarterly) | 54.37M |
| Total Expenses (Quarterly) | 51.30M |
| EPS Diluted (Quarterly) | 0.0282 |
| Gross Profit Margin (Quarterly) | 96.06% |
| Profit Margin (Quarterly) | 5.63% |
| Earnings Yield | -16.64% |
| Normalized Earnings Yield | -16.64 |